节点文献

肠乐康散剂Ⅰ期临床耐受性试验

The tolerance of changlekang powder in phase I clinical trials

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 王世岭; 熊德鑫; 马建丽; 张鉴; 汤旦林; 崔云龙; 万阜昌;

【Author】 WANG Shi-ling1,XIONG De-xin1,MA Jian-li1,ZHANG Jian2, TANG Dan-lin3,CUI Yun-long4,WAN Fu-chang4 (1No. 304 Hospital of PLA,Beijing 100037,China;2Shandong Provincial Hospital, Jinan 250021,China;3Sino-Japan Friendship Hospital,Beijing 100029,China; 4Bei

【机构】 解放军第304医院!北京100037; 山东省立医院!济南250021; 中日友好医院!北京100029; 北京东方百信生物技术有限公司!北京100037;

【摘要】 目的 :观察和评价人体对肠乐康散剂的耐受性和安全性 ,推荐临床用药剂量。方法 :将 30例健康受试者随机均分为 0 .5 ,1.0和 2 .0 g 3个剂量组 ,po ,bid ,共 10d。试验前后作肠道菌群培养分析。 结果 :除肠乐康散剂 4.0 g·d-1剂量组使食欲增加外 ,未见异常反应。肠道菌群培养结果表明有益菌有增加趋势。结论 :肠乐康散剂安全性大 ,耐受性好 ,推荐Ⅱ期临床使用剂量为 po,1.0~ 1.5 g ,bid。

【Abstract】 Objectives:To evaluate the tolerance and safety of changlekang(CLK) and to determine its dose.Methods:30 healthy volunteers were randomly and equally divided to receive twice daily oral dose of 0.5g,1.0g,or 2.0g of CLK powder for 10d.The colonies in intestinal tract were cultured and analyzed before and after treatment.Results:The appetite of volunteers in group of twice daily dose of 2.0g was increased and no abnormal reactions were observed.It was indicated that the beneficial bacteria in intestinal tract tend to be increased after culture.Conclusion:CLK powder is tolerable and safe with a recommended twice daily oral dose of 1.0~1.5g.

【基金】 国家新药基金重点科技(攻关)项目!十个新药的研究与产业化开发 (96-90 1-0 5 -14 5 )
  • 【文献出处】 中国新药杂志 ,Chinese New Drugs Journal , 编辑部邮箱 ,2001年06期
  • 【分类号】R969
  • 【被引频次】2
  • 【下载频次】59
节点文献中: